In the KEYNOTE-826 trial, the addition of the PD-1 inhibitor pembrolizumab to standard-of-care chemotherapy significantly prolonged progression-free survival and overall survival in patients with metastatic, recurrent, or persistent cervical cancer. These findings could define the new standard of care in these cases.

You do not currently have access to this content.